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PERUVIAN EXPERIENCE ON THE HUMAN IMMUNODEFICIENCY
VIRUS DIAGNOSTIC FLOWCHART
EXPERIENCIA PERUANA SOBRE EL FLUJOGRAMA DE DIAGNÓSTICO DEL VIRUS DE
INMUNODEFICIENCIA HUMANA
Eduardo Miranda-Ulloa1,a, Soledad Romero-Ruiz 1,b, Maribel Acuña1,b, Ronal Briceño-Espinoza1,c,
George Obregon1,d, Dilan Suárez-Agüero1,e

Mr. Editor
The Joint United Nations Program on HIV/AIDS (UNAIDS) proposed as a goal that the countries reach 95-95-95
by the year 2030, in other words, that 95% of people living with HIV (PLH) are diagnosed and of these that 95%
receive antiretroviral treatment (ART) and at least 95% have undetectable viral load or viral suppression(1).
En el 2014 el Perú alcanzó la fórmula 64-46-36, por estas razones el Ministerio de Salud (MINSA) realiza
numerosos esfuerzos para cerrar brechas y lograr este objetivo, es por ello que con base en la evidencia,
periódicamente se modi can las fórmulas técnicas. estándares de salud para mejorar la cobertura y el
abordaje de las PLH(2).
In order to close the rst gap, that is, the rst 95, the MINSA began expanding the coverage of HIV diagnosis a
few years ago through the use of rapid tests at all levels of care in the health system, as This is why the World
Health Organization has recommended modi cations in the diagnostic owcharts, which shorten the time to
de ne a person with HIV infection and that he or she can receive early treatment (3).
The HIV diagnosis owcharts for people over 18 months of age, which are contained in the three technical
health standards currently in force, de ne a case of HIV infection as those people who have two reactive
results to two screening tests from diﬀerent manufacturers. or of a diﬀerent principle, considering screening
tests to be the Rapid Test (RT), Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence (CLIA) and
Electrochemiluminescence (ECLIA). It is important to highlight the following cases as cases: a) two reactive
results of two third-generation RPs from diﬀerent manufacturers b) two reactive results of two RPs, one thirdgeneration and one fourth-generation c) One third- or fourth-generation RP generation and an ELISA or
equivalent with reactive results d) A third or fourth generation RP with a reactive result and a positive
con rmatory test: viral load, indirect immuno uorescence (IIF) or immunoblot(4,6).
In the novelty of these owcharts, the consideration of two reactive results to two screening tests as a case of
HIV infection is highlighted(4,5) ; however, there is currently no relevant information on the experience of its
applicability in the Peruvian population. For these reasons, the following objective was set: Identify the results
of con rmatory HIV serological tests in Peruvian samples with two reactive results to two diﬀerent screening
tests.
An observational descriptive study was carried out during November 2021 at the National Reference
Laboratory for Sexually Transmitted Viruses HIV/AIDS of the National Institute of Health (INS); Secondary data
of diagnostic results were analyzed without access to patient identi cation, so it did not require the approval
of an ethics committee since it was a necessity in national HIV surveillance to have information to provide
technical guidance to the healthcare workers.
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The search was carried out for the screening results
recorded in the diagnostic les that were sent by the
diﬀerent health establishments in Peru to the INS for the
con rmation of HIV in the period from January 1 to
December 30, 2019. Likewise, the results of the
con rmatory serological tests issued by the INS were
obtained from the work protocols and the NetLab 1
laboratory information system.

Among the results, it was determined that of a total of
7,858 samples received, 1,543 had two reactive results to
two diﬀerent screening tests (age group: from eighteen
months to thirteen years = 12; from fourteen to
seventeen years = 39; years = 1492) at the same time it is
evident among the main ndings that 98.6%
(1522/1543) had a concordant positive result by means
of the con rmator y serological tests (IFI and
Immunoblot) (See gure N° 1)

Review of HIV con rmatory diagnosis
request forms
n= 7858 (Year: 2019)

6315 les were excluded for not
having two reactive screening
test for VIH

Sheets with two diﬀerent HIV reactive
screening tests
n=1543

Review of the results issued by
the National Institute of Health
(work protocols and NetLab-1)

Con rmatory test results IIF andlor Immunoblot plus HIV
ELISA

HIV positive
n= 1522
(98,6%)

HIV negative
n= 21
(1,4%)

Figure 1. Flowchart of samples incorporated into the study
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people with anti-HLA
antibodies,
neoplasms,
autoimmune diseases and in multiparous women(3).

It is important to highlight that only 1.4% (21/1543) had
negative results for HIV, verifying that this small
percentage that had the condition of de ned case for
HIV, showed to be false reagents. However, it is
important to highlight that the diagnostic owchart
indicates that all cases with two reactive screening test
results should immediately undergo the HIV viral load
test (test considered con rmatory and baseline for the
start of monitoring) before starting ART(4,5). This fraction
of cases could be identi ed as undetectable by the viral
load test (viral RNA), so only these few samples should be
referred to for serological con rmation, because there
would be a risk of administering ART to patients who
actually are HIV negative.

The high concordance demonstrated in the studied
samples that were positive to the con rmatory
serological tests (98.6%) allows us to show that the HIV
diagnosis owchart in the Peruvian population presents
a high reliability in its application, consequently the
results obtained allow us to indicate that samples with
two reactive results to screening tests should not be
referred for serological con rmation (IIF and
Immunoblot) and should be sent directly for viral load
analysis; in this way, patients would access timely ART.

It should be noted that there are reports that HIV
screening tests can generate false reactive results in
hemolyzed, lipemic or contaminated samples, also in

This experience allows us to conclude that the HIV
diagnosis owchart in people older than 18 months
works with high reliability in Peru.
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